As our glioblastoma cohort contained only 3 IDH1 mutant tumours, the impact of the IDH1R132H mutation on HIF-hydroxylase activity, or on the association between ascorbate and the HIF-pathway, is intriguing but could not be assessed. This evidence concerns the gene IDH1 and neoplasm.